Ovarian cancer is a heterogeneous, rapidly progressive, highly lethal disease of low
prevalence. The etiology remains poorly understood. Numerous risk factors have been …

Each year in the United States over 15,000 women die of epithelial ovarian cancer (EOC)
and 22,000 are diagnosed with the disease. The incidence of ovarian cancer has remained …

Ovarian cancer is the most lethal gynecologic malignancy. Efforts at early detection and new
therapeutic approaches to reduce mortality have been largely unsuccessful, because the …

Background CA125, human epididymis protein 4 (HE4), mesothelin, B7-H4, decoy receptor
3 (DcR3), and spondin-2 have been identified as potential ovarian cancer biomarkers …

Background: Screening is an unsolved problem for ovarian cancer (OvCA). As late detection
is equivalent to poor prognosis, we analysed whether OvCA patients show diagnostically …

Women who do not have a documented germline mutation or who do not have a strong
family history suspicious for a germline mutation are considered to be at average risk of …

The HE4 protein is overexpressed in ovarian carcinomas and can be detected in serum by
an ELISA with sensitivity similar to CA125 and higher specificity for malignant disease. We …

Background Ovarian carcinoma represents about 4% of all cancers diagnosed in women
worldwide. Mortality rate is high, over 50%, mainly due to late diagnosis. Currently there are …

Since it was first described in 1981, CA125 has held an important role in monitoring patients
with ovarian cancer. CA125 is elevated in 80% of patients with epithelial ovarian cancer at …

Current clinical use of biomarkers for epithelial ovarian ca... : Current Opinion in Oncology
Current clinical use of biomarkers for epithelial ovarian cancer : Current Opinion in …